Plunkett Research Online: Critical Outcome Techno

CRITICAL OUTCOME TECHNO (COT:TSX) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company’s lead clinical research, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene and the second clinical research, COTI-219, is a novel oral small molecule compound targeting the mutant forms. Th.....



Critical Outcome Techno
Ticker: COT
Exchange: TSX
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 519 858-5157
Fax: 1 519 858-5179
Address: 100 Collip Circle
Suite 230B, The Mogenson Centre
London, ON N6G 4X8 Canada

Types Of Business
Industry Ranks

Industry NAICS code:


Ranks not available
ContactsDescription
Alison SilvaCEO/Director/President
Gene KellyCFO
See More
Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company’s lead clinical research, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene and the second clinical research, COTI-219, is a novel oral small molecule compound targeting the mutant forms. Th.....See More See More

Auditor: KPMG
Legal Advisor:
$USD, In whole numbers,
except marked * or %
201720162015201420132012
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: